- Home
- JAGX vs ZVSA Comparison
JAGX vs ZVSA Comparison
Compare JAGX & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- ZVSA
- Stock Information
- Founded
- JAGX 2013
- ZVSA 2014
- Country
- JAGX United States
- ZVSA United States
- Employees
- JAGX N/A
- ZVSA N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- ZVSA Health Care
- Exchange
- JAGX Nasdaq
- ZVSA Nasdaq
- Market Cap
- JAGX 3.1M
- ZVSA 3.5M
- IPO Year
- JAGX N/A
- ZVSA N/A
- Fundamental
- Price
- JAGX $4.67
- ZVSA $0.59
- Analyst Decision
- JAGX
- ZVSA Strong Buy
- Analyst Count
- JAGX 0
- ZVSA 1
- Target Price
- JAGX N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- JAGX 39.3K
- ZVSA 125.6K
- Earning Date
- JAGX 03-31-2025
- ZVSA 05-14-2025
- Dividend Yield
- JAGX N/A
- ZVSA N/A
- EPS Growth
- JAGX N/A
- ZVSA N/A
- EPS
- JAGX N/A
- ZVSA N/A
- Revenue
- JAGX $11,689,000.00
- ZVSA N/A
- Revenue This Year
- JAGX $18.18
- ZVSA N/A
- Revenue Next Year
- JAGX $40.06
- ZVSA N/A
- P/E Ratio
- JAGX N/A
- ZVSA N/A
- Revenue Growth
- JAGX 19.75
- ZVSA N/A
- 52 Week Low
- JAGX $4.40
- ZVSA $0.58
- 52 Week High
- JAGX $540.00
- ZVSA $8.05
- Technical
- Relative Strength Index (RSI)
- JAGX 20.41
- ZVSA 27.23
- Support Level
- JAGX $4.41
- ZVSA $0.69
- Resistance Level
- JAGX $4.97
- ZVSA $0.65
- Average True Range (ATR)
- JAGX 0.88
- ZVSA 0.06
- MACD
- JAGX 0.09
- ZVSA -0.00
- Stochastic Oscillator
- JAGX 3.35
- ZVSA 3.04
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.